Use of Export in Primary Percutaneous Coronary Intervention

Launched by NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES, PAKISTAN · Aug 19, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a treatment approach for patients experiencing a heart attack, specifically a type called ST-segment Elevation Myocardial Infarction (STEMI). The study aims to compare two methods: one where doctors use a technique called manual thrombus aspiration to remove blood clots before performing a procedure known as percutaneous coronary intervention (PCI), and another where they perform PCI alone without the aspiration. The goal is to see which method leads to better outcomes for patients.

To be eligible to participate, patients must be experiencing chest pain that has lasted for at least 30 minutes and have clear signs of a STEMI on their heart monitor. They should also have had a complete blockage of a coronary artery for less than 12 hours and be scheduled for a primary PCI. However, patients who have had previous heart surgeries or certain severe conditions will not be included. If someone participates, they can expect to receive standard care while helping researchers learn more about the best treatment options for heart attacks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients presenting with:-Symptoms of myocardial ischemia lasting for ≥30 minutes
• • Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads
• • Chest pain \< 12 hours duration
• • Total occlusion (TIMI 0 flow)
• • Patients undergoing primary PCI
• • Informed consent
• Exclusion Criteria:
• • Patients with prior history of cardiac related surgery or intervention
• • Performance of a rescue PCI after thrombolysis
• • Known existence of a disease resulting in a life expectancy of less than 6 months
• • Killip class III, IV